Insights on the Canine Atopic Dermatitis Global Market to 2027 - Increasing Occurrence of CAD in Domesticated Dogs Drives Growth
January 06, 2023 06:58 ET
|
Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
December 05, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Atopic...
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
November 15, 2022 16:01 ET
|
Evelo Biosciences, Inc.
Peer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 ...
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022 11:10 ET
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022 17:27 ET
|
Evelo Biosciences, Inc.
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first...
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
November 08, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
September 07, 2022 17:00 ET
|
Arcutis Biotherapeutics, Inc.
Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisLead indication, atopic dermatitis, is a rapidly...
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
September 07, 2022 01:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
August 23, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trialTopline data from both INTEGUMENT-1 and -2 trials expected by end of 2022Atopic dermatitis affects...